<DOC>
	<DOCNO>NCT00489268</DOCNO>
	<brief_summary>This study conduct 2 serial phase ( dosimetry phase effectiveness phase ) evaluate balloon-based ablation device ( HALO360 ) deliver pre-set amount energy density ( J/cm2 ) barrett 's tissue . The dosimetry phase evaluate dose-response safety deliver 6 12 J/cm2 . The effectiveness phase use 10 J/cm2 deliver twice patient , follow Esophagogastroduodenoscopy ( EGD ) biopsies 1 , 3 , 6 , 12 month . A second ablation procedure perform Barretts esophagus ( BE ) present 1 3 month . A complete response ( CR ) define biopsy specimen negative Barrett 's Esophagus 12 month . The effectiveness phase present study extend 2.5-year follow-up . This trial incorporate opportunity persistent BE treat focal ablation device ( HALO90 ) , achieve CR 98.4 % patient 2.5-year follow-up , result publish . There ample evidence RadioFrequency Ablation ( RFA ) Barrett 's esophagus effective safe . Having additional follow-up ( 5 year ) would add valuable information literature , thus aid physician make patient management decision appropriate follow-up interval RFA .</brief_summary>
	<brief_title>Micro-Layer Ablation Barrett 's Metaplasia- A Two-Phase , Multi-Center Trial - Extension Follow-up 5 Years</brief_title>
	<detailed_description>This study intend gather additional information regard performance bipolar balloon electrode device ( HALO360 ) utilize radiofrequency ( RF ) energy micro-layer ablation Barrett 's esophagus , precancerous , metaplastic change esophageal lining . The device receive 510 ( k ) clearance specific indication , include treatment Barrett 's esophagus . This study conduct two phase intend evaluate effect micro-layer ablation Barrett 's metaplasia use 510 ( k ) clear , bipolar , balloon electrode device . Phase I ( n=30 ) intend provide additional information regard effect three randomize treatment parameter ( energy setting , Joules/cm2 ) . Phase II ( n=70 ) intend provide additional information regard effect optimal technique energy density setting ( Joules/cm2 ) determine 1-month endoscopy result Phase I . Phase 2 primary endpoint histological clearance Barrett 's ( % patient ) . This trial incorporate opportunity persistent BE treat focal ablation device ( HALO90 ) , 2.5-year follow-up , achieve CR 98.4 % patient . Having additional follow-up ( 5 year ) would add valuable information literature , thus aid physician make patient management decision appropriate follow-up interval RFA . This study allow collection 5-year follow-up biopsy , thereafter , offer RFA subject persistent Barrett 's . Upon approval present amendment protocol ( B-200-5 year extension ) inform consent form ( ICF ) study site , subject participate B-200-2.5 year extension biopsy 2.5 year initial enrollment offer participation extension .</detailed_description>
	<mesh_term>Barrett Esophagus</mesh_term>
	<mesh_term>Metaplasia</mesh_term>
	<criteria>1 . Subject document histopathological diagnosis Barrett 's metaplasia ( without dysplasia ) follow : biopsy obtain less 6 month prior enrollment , biopsy obtain review investigator institution , biopsy protocol include least 4 quadrant biopsy per 2 cm length Barrett 's metaplasia 2 . Barrett metaplasia endoscopic length : Phase I : 23 cm Barrett 's length ( inclusive ) Phase II : 26 cm Barrett 's length ( inclusive ) 3 . Age 1875 year inclusive 4 . Subject agree participate , fully understand content informed consent form , sign inform consent form 5 . Five year extension : All subject participate B2002.5 year extension biopsy 2.5 year initial enrollment ( n=61 ) offer participation extension . 1 . Subjects pregnant plan pregnancy 2 . Esophageal stricture prevent passage endoscope catheter 3 . Active esophagitis ( HetzelDent Grade III IV ) describe erosion ulceration encompass 10 % distal esophagus 4 . Barrett 's metaplasia dysplasia ( previous biopsy ) 5 . History current diagnosis malignancy esophagus 6 . Prior radiation therapy esophagus , except head neck region radiation therapy 7 . Any previous ablative therapy within esophagus ( photodynamic therapy , multipolar electrical coagulation , argon plasma coagulation , laser treatment , ) 8 . Any previous endoscopic mucosal resection within esophagus 9 . Any previous esophageal surgery , except fundoplication 10 . Esophageal varix 11 . Subject implantable pacing device ( example ; AICD , neurostimulator , cardiac pacemaker ) receive clearance enrollment study specialist responsible pacing device 12 . Participation another clinical study past 60 day 13 . Subject suffers unstable psychiatric disorder ( )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Barrett 's Esophagus</keyword>
	<keyword>Intestinal Metaplasia</keyword>
	<keyword>Radiofrequency Ablation</keyword>
</DOC>